Eric Klug News Today

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

The novel agent has shown no immunogenicity issues thus far and might be a promising new PCSK9 inhibitor option.

90% of high-risk patients on lerodalcibep achieved guideline-recommended cholesterol targets

Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.

Dr Erin D. Michos provides highlights from ACC 2024, including anticipated presentations, quick takeaways, and insights into how the presented research will impact patients.

With the rate of Covid-19 cases decreasing, the rate of heart-related illnesses since Covid-19 has seen a sky-rocketing increase.

Urgent action is needed to stop and reverse the steep rise in heart failure happening across the Middle East and Africa (MEA). This was the warning issued by a group of regional experts, who collectively outlined the primary gaps in awareness, diagnosis and prevention of heart failure in the region…

its a big day for apple as hundreds of people are lined up at west moscone center. what may be unveiled today. "mornings on 2" starts right now. well, good morning. welcome to a brand-new day, monday, june 10th. welcome to "mornings on 2." im dave clark. >> good morning. im it -- im tori campbell. lets lets gee ginn with weather. i saw some rain. >> yeah. theres lots of reports of rain and lightning from livermore and san jose. this whole system will be with us today. i think this ...